Market Research > Industries > Healthcare

Market Research: Nonprescription Drugs Canada 2002

Nonprescription Drugs Canada 2002 - Archived Report

Published July 2003

View PDF brochure

This study provides an in-depth analysis of Canada’s nonprescription drug industry 2002, including 25 product categories and profiles of 15 major over-the-counter drug manufacturers. The report provides information on sales and market share of leading brands and private-label products, advertising and promotional activity, retail distribution, regulatory activity, competition from alternative medicines, new product activity, and five-year forecasts. (Y228E)

	ORDER ONLINE

You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

FULL REPORT [US$ 17 550 (seventeen thousand five hundred fifty US Dollars]

INTRODUCTION [US$ 0]

Table 1-1 ACRONYMS AND ABBREVIATIONS USED IN THIS REPORT

INDUSTRY ANALYSIS [US$ 3 500]

PRODUCTS [US$ 5 275]

OVERVIEW [US$ 275]

Figure 3A-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CLASS, 2002
Table 3A-1 MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS BY PRODUCT CATEGORY, 2001 AND 2002

COUGH AND COLD PREPARATIONS [US$ 1 325]

Figure 3B-1 MANUFACTURERS’ SALES OF COUGH AND COLD PREPARATIONS BY SEGMENT, 2002
Table 3B-1 MANUFACTURERS’ SALES OF COUGH AND COLD PREPARATIONS, 2001 AND 2002

ALLERGY RELIEF PRODUCTS [US$ 275]

Table 3B 3 MANUFACTURERS’ SALES OF ALLERGY RELIEF PRODUCTS BY BRAND, 2001 AND 2002
Table 3B-4 SALES OF ALLERGY PRODUCTS BY RETAIL OUTLET

COLD MEDICATIONS [US$ 325]

Table 3B-5 NEW COLD MEDICATIONS INTRODUCED IN 2001 AND 2002
Table 3B-6 MANUFACTURERS’ SALES OF COLD MEDICATIONS BY BRAND, 2001 AND 2002
Table 3B-7 MAJOR MANUFACTURERS’ SALES OF COLD PRODUCTS
Table 3B-8 RETAIL OUTLET DISTRIBUTION OF COLD MEDICATIONS, 2001 AND 2002

COUGH SYRUPS [US$ 275]

Table 3B-9 NEW COUGH SYRUPS INTRODUCED IN 2001 AND 2002
Table 3B-10 MANUFACTURERS’ SALES OF COUGH SYRUPS BY BRAND, 2001 AND 2002
Table 3B-11 RETAIL DISTRIBUTION OF COUGH SYRUPS, 2001 AND 2002

LOZENGES AND DROPS [US$ 275]

Table 3B-12 NEW LOZENGES AND DROPS INTRODUCED IN 2001 AND 2002
Table 3B-13 MANUFACTURERS’ SALES OF LOZENGES AND DROPS BY BRAND, 2001 AND 2002
Table 3B-14 RETAIL OUTLET DISTRIBUTION OF LOZENGES AND DROPS, 2001 AND 2002

NASAL DECONGESTANTS [US$ 200]

Table 3B-15 MANUFACTURERS’ SALES OF NASAL DECONGESTANTS, 2001 AND 2002
Table 3B-16 RETAIL OUTLET DISTRIBUTION OF NASAL DECONGESTANTS, 2001 AND 2002

SINUS REMEDIES [US$ 200]

Table 3B-17 NEW SINUS REMEDIES INTRODUCED IN 2001 AND 2002
Table 3B-18 MANUFACTURERS’ SALES OF SINUS REMEDIES, 2001 AND 2002
Table 3B-19 RETAIL OUTLET DISTRIBUTION OF SINUS REMEDIES, 2001 AND 2002

DIGESTIVE PRODUCTS [US$ 800]

Figure 3C-1 MANUFACTURERS’ SALES OF DIGESTIVE PRODUCTS, 2002
Table 3C-1 MANUFACTURERS’ SALES OF DIGESTIVE PRODUCTS, 2001 AND 2002

ANTACIDS [US$ 275]

Table 3C-2 NEW ANTACIDS INTRODUCED IN 2001 AND 2002
Table 3C-3 MANUFACTURERS’ SALES OF ANTACIDS, 2001 AND 2002
Table 3C-4 RETAIL OUTLET DISTRIBUTION OF ANTACIDS, 2001 AND 2002

ANTIDIARRHEALS [US$ 200]

Table 3C-5 NEW ANTIDIARRHEALS INTRODUCED IN 2001 AND 2002
Table 3C-6 MANUFACTURERS’ SALES OF ANTIDIARRHEALS, 2001 AND 2002
Table 3C-7 RETAIL OUTLET DISTRIBUTION OF ANTIDIARRHEALS, 2001 AND 2002

LAXATIVES [US$ 225]

Table 3C-8 NEW LAXATIVES INTRODUCED IN 2001 AND 2002
Table 3C-9 MANUFACTURERS’ SALES OF LAXATIVES BY BRAND, 2001 AND 2002
Table 3C-10 SALES OF PRIVATE-LABEL LAXATIVES BY SEGMENT, 2001 AND 2002
Table 3C-11 RETAIL OUTLET DISTRIBUTION OF LAXATIVES, 2001 AND 2002

OTHER DIGESTIVE PRODUCTS [US$ 200]

Table 3C-12 NEW OTHER DIGESTIVE PRODUCTS INTRODUCED IN 2002
Table 3C-13 MANUFACTURERS’ SALES OF OTHER DIGESTIVE PRODUCTS, 2001 AND 2002
Table 3C-14 RETAIL OUTLET DISTRIBUTION OF OTHER DIGESTIVE PRODUCTS, 2001 AND 2002

INTERNAL ANALGESICS [US$ 800]

Figure 3D-1 MANUFACTURERS’ SALES OF INTERNAL ANALGESICS BY SEGMENT, 2002
Table 3D-1 MANUFACTURERS’ SALES OF INTERNAL ANALGESICS, 2001 AND 2002
Table 3D-2 NEW INTERNAL ANALGESICS INTRODUCED IN 2001 AND 2002
Table 3D-3 MANUFACTURERS’ SALES OF INTERNAL ANALGESICS BY BRAND, 2001 AND 2002
Table 3D-4 RETAIL OUTLET DISTRIBUTION OF INTERNAL ANALGESICS, 2001 AND 2002

NUTRITIONAL PRODUCTS [US$ 800]

Figure 3E-1 MANUFACTURERS’ SALES OF NUTRITIONAL PRODUCTS BY SEGMENT, 2002
Table 3E-1 MANUFACTURERS’ SALES OF NUTRITIONAL PRODUCTS, 2001 AND 2002

DIET AIDS [US$ 225]

Table 3E 3 MANUFACTURERS’ SALES OF DIET AIDS BY BRAND, 2001 AND 2002
Table 3E-4 RETAIL OUTLET DISTRIBUTION OF DIET AIDS, 2001 AND 2002

HERBAL PRODUCT [US$ 325]

Table 3E-5 NEW HERBAL PRODUCTS INTRODUCED IN 2001 AND 2002
Table 3E-6 COMMON HERBAL PRODUCTS AND TYPICAL USES
Table 3E-7 MANUFACTURERS’ SALES OF HERBAL PRODUCTS, 2001 AND 2002
Table 3E-8 PRIVATE-LABEL SALES OF HERBAL PRODUCTS, 2001 AND 2002
Table 3E-9 RETAIL OUTLET DISTRIBUTION OF HERBAL PRODUCTS, 2001 AND 2002

VITAMINS AND MINERALS [US$ 325]

Table 3E-10 NEW VITAMINS AND MINERALS INTRODUCED IN 2001 AND 2002
Table 3E-11 MANUFACTURERS’ SALES OF VITAMINS AND MINERALS, 2001 AND 2002
Table 3E-12 MANUFACTURERS’ SALES OF VITAMINS AND MINERALS BY SEGMENT, 2001 AND 2002
Table 3E-13 PRIVATE-LABEL SALES OF VITAMINS AND MINERALS BY SEGMENT, 2001 AND 2002
Table 3E-14 RETAIL OUTLET DISTRIBUTION OF VITAMINS AND MINERALS, 2001 AND 2002

TOPICAL PRODUCTS [US$ 1 325]

Figure 3F-1 MANUFACTURERS’ SALES OF TOPICAL PRODUCTS, 2002
Table 3F-1 MANUFACTURERS’ SALES OF TOPICAL PRODUCTS, 2001 AND 2002

ACNE AIDS [US$ 200]

Table 3F-2 NEW ACNE AIDS INTRODUCED IN 2001 AND 2002
Table 3F-3 MANUFACTURERS’ SALES OF ACNE AIDS BY BRAND, 2001 AND 2002
Table 3F-4 MANUFACTURERS’ SALES OF ACNE AIDS BY RETAIL OUTLET

CONTACT LENS SOLUTIONS [US$ 200]

Table 3F-5 NEW CONTACT LENS SOLUTIONS INTRODUCED IN 2002
Table 3F-6 MANUFACTURERS’ SALES OF CONTACT LENS SOLUTIONS, 2001 AND 2002
Table 3F-7 RETAIL DISTRIBUTION OF CONTACT LENS SOLUTIONS, 2001 AND 2002

DIAPER RASH PRODUCTS [US$ 125]

Table 3F-8 MANUFACTURERS’ SALES OF DIAPER RASH PRODUCTS, 2001 AND 2002
Table 3F-9 RETAIL OUTLET DISTRIBUTION OF DIAPER RASH PRODUCTS, 2001 AND 2002

EYE CARE PRODUCTS [US$ 200]

Table 3F-10 NEW EYE CARE PRODUCTS INTRODUCED IN 2002
Table 3F-11 MANUFACTURERS’ SALES OF EYE CARE PRODUCTS BY BRAND, 2001 AND 2002
Table 3F-12 RETAIL OUTLET DISTRIBUTION OF EYE CARE PRODUCTS, 2001 AND 2002

FEMININE YEAST INFECTION REMEDIES [US$ 200]

Table 3F-13 NEW FEMININE YEAST INFECTION REMEDIES INTRODUCED IN 2002
Table 3F-14 MANUFACTURERS’ SALES OF FEMININE YEAST INFECTION REMEDIES, 2001 AND 2002
Table 3F-15 RETAIL OUTLET DISTRIBUTION OF FEMININE YEAST INFECTION REMEDIES, 2001 AND 2002

FIRST AID PRODUCTS [US$ 200]

Table 3F-16 NEW FIRST AID PRODUCTS INTRODUCED IN 2001 AND 2002
Table 3 17 MANUFACTURERS’ SALES OF FIRST AID PRODUCTS BY BRAND, 2001 AND 2002
Table 3F-18 RETAIL OUTLET DISTRIBUTION OF FIRST AID PRODUCTS, 2001 AND 2002

FOOT CARE PRODUCTS [US$ 200]

Table 3F-19 NEW FOOT CARE PRODUCTS INTRODUCED IN 2001 AND 2002
Table 3F 20 MANUFACTURERS’ SALES OF FOOT CARE PRODUCTS BY BRAND, 2001 AND 2002
Table 3F-21 RETAIL OUTLET DISTRIBUTION OF FOOT CARE PRODUCTS, 2001 AND 2002

HEMORRHOIDAL PREPARATIONS [US$ 125]

Table 3F-22 MANUFACTURERS’ SALES OF HEMORRHOIDAL PREPARATIONS BY BRAND, 2001 AND 2002
Table 3F-23 RETAIL OUTLET DISTRIBUTION OF HEMORRHOIDAL PREPARATIONS, 2001 AND 2002

TOPICAL ANALGESICS [US$ 125]

Table 3F-24 NEW TOPICAL ANALGESICS INTRODUCED IN 2001 AND 2002
Table 3F 25 MANUFACTURERS’ SALES OF TOPICAL ANALGESICS BY BRAND, 2001 AND 2002
Table 3F-26 RETAIL OUTLET DISTRIBUTION OF TOPICAL ANALGESICS, 2001 AND 2002

MISCELLANEOUS PRODUCTS [US$ 800]

Figure 3G-1 MANUFACTURERS’ SALES OF MISCELLANEOUS PRODUCTS, 2002
Table 3G-1 MANUFACTURERS’ SALES OF MISCELLANEOUS PRODUCTS, 2001 AND 2002

HOME DIAGNOSTIC TEST KITS [US$ 400]

Table 3G-2 NEW HOME DIAGNOSTIC TEST KITS INTRODUCED IN 2001 AND 2002
Table 3G-3 MANUFACTURERS’ SALES OF HOME DIAGNOSTIC TEST KITS, 2001 AND 2002

SLEEPING AIDS [US$ 200]

Table 3G-5 NEW SLEEPING AIDS INTRODUCED IN 2002
Table 3G-6 MANUFACTURERS’ SALES OF SLEEPING AIDS, 2001 AND 2002
Table 3G-7 RETAIL OUTLET DISTRIBUTION OF SLEEPING AIDS, 2001 AND 2002

SMOKING CESSATION AIDS [US$ 275]

Table 3G-8 MANUFACTURERS’ SALES OF SMOKING CESSATION AIDS 2001 AND 2002
Table 3G-9 RETAIL DISTRIBUTION OF SMOKING CESSATION AIDS, 2001 AND 2002

MAJOR COMPANIES[US$ 5 275]

Table 4 1 LEADING MANUFACTURERS’ SALES OF NONPRESCRIPTION DRUGS, 2002

ABBOTT LABORATORIES [US$ 275]

Table 4-2 ABBOTT LABORATORIES’ SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 3 FORECAST GROWTH OF ABBOTT LABORATORIES’ NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

BAUSCH & LOMB [US$ 275]

Table 4-4 BAUSCH & LOMB’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 5 FORECAST GROWTH OF BAUSCH & LOMB’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

BAYER GROUP [US$ 800]

Table 4-6 BAYER GROUP’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-7 NEW PRODUCTS LAUNCHED BY BAYER GROUP, 2001 AND 2002
Table 4 8 FORECAST GROWTH OF BAYER GROUP’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

CHURCH & DWIGHT [US$ 525]

Table 4-9 CHURCH & DWIGHT’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 11 FORECAST GROWTH OF CHURCH & DWIGHT’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

GLAXOSMITHKLINE [US$ 800]

Table 4-12 GLAXOSMITHKLINE’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-13 NEW PRODUCTS LAUNCHED BY GLAXOSMITHKLINE, 2001 AND 2002
Table 4 14 FORECAST GROWTH OF GLAXOSMITHKLINE’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

JAMIESON LABORATORIES [US$ 275]

Table 4-15 JAMIESON LABORATORIES’ SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-16 NEW PRODUCTS LAUNCHED BY JAMIESON LABORATORIES, 2001 AND 2002
Table 4 17 FORECAST GROWTH OF JAMIESON LABORATORIES’ NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

JOHNSON & JOHNSON [US$ 800]

Table 4-18 JOHNSON & JOHNSON’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-19 NEW PRODUCTS LAUNCHED BY JOHNSON & JOHNSON, 2001 AND 2002
Table 4 20 FORECAST GROWTH OF JOHNSON & JOHNSON’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

JOHNSON & JOHNSON-MERCK CONSUMER PHARMACEUTICALS COMPANY [US$ 275]

Table 4-21 JOHNSON & JOHNSON-MERCK’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 22 FORECAST GROWTH OF JOHNSON & JOHNSON-MERCK’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

NOVARTIS [US$ 800]

Table 4-23 NOVARTIS’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-24 NEW PRODUCTS LAUNCHED BY NOVARTIS, 2001 AND 2002
Table 4 25 FORECAST GROWTH OF NOVARTIS’ NONPRESCRIPTION DRUGS BYCATEGORY, 2002 TO 2007

PERRIGO [US$ 525]

Table 4-26 PERRIGO’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 27 FORECAST GROWTH OF PERRIGO’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

PFIZER [US$ 800]

Table 4-28 PFIZER’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-29 NEW PRODUCTS LAUNCHED BY PFIZER, 2001 AND 2002
Table 4 30 FORECAST GROWTH OF PFIZER’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

PROCTER & GAMBLE [US$ 275]

Table 4-31 PROCTER & GAMBLE’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 32 FORECAST GROWTH OF PROCTER & GAMBLE’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

ROCHE HOLDINGS LTD. [US$ 275]

Table 4-33 ROCHE HOLDINGS’ SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4 34 FORECAST GROWTH OF ROCHE HOLDINGS’ NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

SCHERING-PLOUGH [US$ 525]

Table 4-35 SCHERING-PLOUGH’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-36 NEW PRODUCTS LAUNC-+HED BY SCHERING-PLOUGH, 2001 AND 2002
Table 4 37 FORECAST GROWTH OF SCHERING-PLOUGH’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

WYETH [US$ 525]

Table 4-38 WYETH’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-39 NEW PRODUCTS LAUNCHED BY WYETH, 2001 AND 2002
Table 4 40 FORECAST GROWTH OF WYETH’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

MINOR COMPANIES [US$ 3 500]

Table 4-38 WYETH’S SALES OF NONPRESCRIPTION DRUGS, 2001 AND 2002
Table 4-39 NEW PRODUCTS LAUNCHED BY WYETH, 2001 AND 2002
Table 4 40 FORECAST GROWTH OF WYETH’S NONPRESCRIPTION DRUGS BY CATEGORY, 2002 TO 2007

MARKET WATCH BULLETIN [US$ 3 500]

INTRODUCTION [US$ 0]

COMPANY DEVELOPMENTS [US$ 1 400]

REGULATORY UPDATE [US$ 1 400]

Table 6-1 NONPRESCRIPTION DRUG INGREDIENTS AND THEIR SCHEDULES
Table 6 2 STATUS OF NATIONAL DRUG SCHEDULES HARMONIZATION BY PROVINCE
Table 6 3 RX-TO-OTC SWITCHES IN CANADA, 1986 TO 2002

NEW PRODUCT INTRODUCTIONS [US$ 1 050]

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.

Market Research: Nonprescription Drugs Canada 2002

Nonprescription Drugs Canada 2002 - Archived Report

ORDER ONLINE

STEP 1 of 3

STEP 2 of 3

STEP 3 of 3

Questions?